Top-Rated StocksTop-RatedNASDAQ:XNCR Xencor (XNCR) Stock Forecast, Price & News $20.16 -0.19 (-0.93%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$20.12▼$20.5350-Day Range$20.35▼$25.3952-Week Range$20.12▼$38.20Volume325,154 shsAverage Volume333,561 shsMarket Capitalization$1.22 billionP/E RatioN/ADividend YieldN/APrice Target$44.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Xencor MarketRank™ ForecastAnalyst RatingBuy3.08 Rating ScoreUpside/Downside119.2% Upside$44.20 Price TargetShort InterestBearish9.24% of Shares Sold ShortDividend StrengthN/ASustainability-2.24Upright™ Environmental ScoreNews Sentiment0.55Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.87) to ($2.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector671st out of 968 stocksPharmaceutical Preparations Industry304th out of 445 stocks 3.5 Analyst's Opinion Consensus RatingXencor has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.20, Xencor has a forecasted upside of 119.2% from its current price of $20.16.Amount of Analyst CoverageXencor has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.24% of the outstanding shares of Xencor have been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 18.4, which indicates bearish sentiment.Change versus previous monthShort interest in Xencor has recently increased by 1.27%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Xencor is -2.24. Previous Next 2.5 News and Social Media Coverage News SentimentXencor has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Xencor this week, compared to 2 articles on an average week.Search Interest6 people have searched for XNCR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Xencor to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.97% of the stock of Xencor is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($2.87) to ($2.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -9.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -9.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xencor (NASDAQ:XNCR) StockXencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.Read More XNCR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XNCR Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Buy" by AnalystsSeptember 20, 2023 | benzinga.comXencor Director Awarded $844K Worth of Stock OptionsSeptember 22, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 17, 2023 | americanbankingnews.comXencor (NASDAQ:XNCR) Sets New 12-Month Low at $20.82August 29, 2023 | fool.comXencor (NASDAQ: XNCR)August 8, 2023 | finance.yahoo.comXencor, Inc. (NASDAQ:XNCR) Q2 2023 Earnings Call TranscriptAugust 8, 2023 | finance.yahoo.comAnalysts Just Published A Bright New Outlook For Xencor, Inc.'s (NASDAQ:XNCR)August 7, 2023 | markets.businessinsider.comBarclays Remains a Sell on Xencor (XNCR)September 22, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.August 5, 2023 | markets.businessinsider.comRBC Capital Remains a Buy on Xencor (XNCR)August 3, 2023 | markets.businessinsider.comMizuho Securities Remains a Buy on Xencor (XNCR)August 3, 2023 | finance.yahoo.comXencor Reports Second Quarter 2023 Financial ResultsJuly 27, 2023 | finance.yahoo.comXencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023July 17, 2023 | seekingalpha.comXencor: Once-Great R&D Behemoth With Emerging New PipelineJune 18, 2023 | finance.yahoo.comInvestors in Xencor (NASDAQ:XNCR) have unfortunately lost 34% over the last five yearsMay 30, 2023 | finance.yahoo.comXencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 CongressMay 19, 2023 | msn.comB of A Securities Initiates Coverage of Xencor (XNCR) with Buy RecommendationMay 19, 2023 | msn.comBank of America Initiates Xencor Coverage with Buy RatingMay 19, 2023 | msn.comXencor a buy at BofA on protein therapeuticsMay 10, 2023 | markets.businessinsider.comWedbush Sticks to Their Buy Rating for Xencor (XNCR)May 10, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About XencorMay 8, 2023 | seekingalpha.comXencor, Inc. (XNCR) Q1 2023 Earnings Call TranscriptMay 1, 2023 | finance.yahoo.comXencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023April 26, 2023 | finance.yahoo.comXencor Appoints Nancy Valente, M.D., as Chief Development OfficerApril 17, 2023 | finance.yahoo.comXencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023March 14, 2023 | finance.yahoo.comXencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023March 14, 2023 | finance.yahoo.comStrength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?See More Headlines Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address XNCR Company Calendar Last Earnings8/03/2023Today9/22/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XNCR CUSIPN/A CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees281Year FoundedN/APrice Target and Rating Average Stock Price Forecast$44.20 High Stock Price Forecast$59.00 Low Stock Price Forecast$36.00 Forecasted Upside/Downside+119.5%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,180,000.00 Net Margins-112.46% Pretax Margin-111.86% Return on Equity-18.14% Return on Assets-15.63% Debt Debt-to-Equity RatioN/A Current Ratio13.30 Quick Ratio13.30 Sales & Book Value Annual Sales$164.58 million Price / Sales7.42 Cash FlowN/A Price / Cash FlowN/A Book Value$12.14 per share Price / Book1.66Miscellaneous Outstanding Shares60,610,000Free Float57,601,000Market Cap$1.22 billion OptionableOptionable Beta0.72 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Bassil I. Dahiyat Ph.D. (Age 53)Co-Founder, CEO, Pres & Director Comp: $1.08MMr. John J. Kuch (Age 64)Sr. VP & CFO Comp: $660.75kDr. John R. Desjarlais Ph.D. (Age 59)Exec. VP of Research & Chief Scientific Officer Comp: $711.45kMs. Celia E. Eckert J.D. (Age 50)Sr. VP, Gen. Counsel & Corp. Sec. Comp: $646.25kDr. Nancy Valente M.D. (Age 64)Exec. VP & Chief Devel. Officer Comp: $28.16kMr. Charles LilesAssociate Director and Head of Corp. Communications & Investor RelationsMs. Jennifer SandozVP of HRDr. Jeremy Grunstein Ph.D.Sr. VP of Bus. Devel.Mr. Kirk Rosemark RAC (Age 58)Sr. VP of Regulatory Affairs & Quality Assurance Mr. Eric P. KowackSr. VP of Program Leadership & Alliance ManagementMore ExecutivesKey CompetitorsOPKO HealthNASDAQ:OPKAmylyx PharmaceuticalsNASDAQ:AMLX89bioNASDAQ:ETNBArvinasNASDAQ:ARVNSummit TherapeuticsNASDAQ:SMMTView All CompetitorsInsiders & InstitutionsBarclays PLCBought 14,591 shares on 9/21/2023Ownership: 0.144%California State Teachers Retirement SystemSold 4,535 shares on 8/21/2023Ownership: 0.110%Teachers Retirement System of The State of KentuckyBought 1,048 shares on 8/21/2023Ownership: 0.032%Nuveen Asset Management LLCBought 33,207 shares on 8/16/2023Ownership: 0.353%Segall Bryant & Hamill LLCBought 647 shares on 8/15/2023Ownership: 0.256%View All Insider TransactionsView All Institutional Transactions XNCR Stock - Frequently Asked Questions Should I buy or sell Xencor stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XNCR shares. View XNCR analyst ratings or view top-rated stocks. What is Xencor's stock price forecast for 2023? 12 equities research analysts have issued 1 year target prices for Xencor's stock. Their XNCR share price forecasts range from $36.00 to $59.00. On average, they anticipate the company's share price to reach $44.20 in the next year. This suggests a possible upside of 119.5% from the stock's current price. View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts. How have XNCR shares performed in 2023? Xencor's stock was trading at $26.04 on January 1st, 2023. Since then, XNCR shares have decreased by 22.7% and is now trading at $20.14. View the best growth stocks for 2023 here. When is Xencor's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our XNCR earnings forecast. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) released its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.54. The biopharmaceutical company had revenue of $45.52 million for the quarter, compared to analysts' expectations of $26.25 million. Xencor had a negative trailing twelve-month return on equity of 18.14% and a negative net margin of 112.46%. The firm's revenue for the quarter was up 50.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.57) EPS. What ETFs hold Xencor's stock? ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH) and iShares Genomics Immunology and Healthcare ETF (IDNA).ALPS Medical Breakthroughs ETF (SBIO). What is Bassil I. Dahiyat's approval rating as Xencor's CEO? 6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN). What is Xencor's stock symbol? Xencor trades on the NASDAQ under the ticker symbol "XNCR." Who are Xencor's major shareholders? Xencor's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.75%), State Street Corp (5.12%), Dimensional Fund Advisors LP (2.60%), Geode Capital Management LLC (2.00%), Northern Trust Corp (1.23%) and Candriam S.C.A. (1.08%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert and John J Kuch. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xencor's stock price today? One share of XNCR stock can currently be purchased for approximately $20.14. How much money does Xencor make? Xencor (NASDAQ:XNCR) has a market capitalization of $1.22 billion and generates $164.58 million in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. How many employees does Xencor have? The company employs 281 workers across the globe. How can I contact Xencor? Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350. This page (NASDAQ:XNCR) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.